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In colorectal cancer, one of the most common malignant tumours,
factors predicting relapse risk in addition to the currently used 
clinicopathological staging systems are needed for several reasons.
A considerable fraction of node-negative colorectal tumours will
recur (Olson et al, 1980) and adjuvant therapy is not routinely
administered for this group (Moertel et al, 1990). Also positive
lymph nodes do not always clearly predict a more unfavourable
outcome (Wolmark et al, 1986). The Dukes’ system has, therefore,
been extended by subdividing each stage according to depth of inva-
sion (American Joint Committee on Cancer, 1988). It is, however,
conceivable that because of inadequate sampling both lymph node
status and depth of mural penetration are inaccurately assessed. The
identification and adjuvant treatment of those stage B and C tumour
patients prone to early relapse might improve the survival of
colorectal cancer patients without the risk of overtreatment.
Angiogenesis is necessary for tumour growth (Folkman et al,
1990) and facilitates two processes responsible for the malignant
phenotype of a growing tumour, i.e. invasion and metastasis
(Liotta et al, 1974; Skobe et al, 1997). Tumour growth kinetics
correlate with the concentration of angiogenic factors in the blood
of advanced colorectal cancer patients (Dirix et al, 1996, 1997).
Although the proliferation fraction of a tumour does not depend on
the number of microvessels, tumour cells are less prone to undergo
apoptosis in well-vascularized tumours (Holmgren et al, 1995; Lu
et al, 1997). Invasion of several in situ carcinoma types can be
predicted by elevated microvessel counts at the other side of the
basement membrane (Hanahan et al, 1996). Quantification of the
density of the vasculature in selected areas of the tumour can
reproducibly predict metastasis, provided a standardized method 
is used (Vermeulen et al, 1996a). Although in different animal
tumour models the angiogenic phenotype or ‘angiogenic switch’ is
related to accelerated growth and metastasis, angiogenesis-
independent growth exists (Pezzella et al, 1997).
The prognostic significance of angiogenesis in patients with
colorectal cancer has been reported, but none of the studies had a
prospective design (Saclarides et al, 1994; Frank et al, 1995;
Takahashi et al, 1995, 1997; Tomisaki et al, 1996; Engel et al,
1996; Takebayashi et al, 1996a, 1996b; Tanigawa et al, 1997).
Most of the few negative studies used a counting technique which
substantially differs from the international consensus method of
intratumoral microvessel density (IMD) assessment (Bossi et al,
1995; Lindmark et al, 1996). We have previously confirmed the
reproducibility of this method in colorectal and breast cancer 
specimens (Vermeulen et al, 1995a, 1997).
Several genes, like p53 and ras, might be responsible for the
angiogenic switch by changing the local balance between pro- and
antiangiogenic factors (Rak et al, 1995). p53 probably regulates
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the thrombospondin 1 (TSP-1) gene in a direct way (Dameron et
al, 1994). The secretion of TSP-1, a potent angiogenesis inhibitor,
is reduced in fibroblasts isolated from Li–Fraumeni patients
because of the in vitro loss of the remaining wild-type p53 allele.
Transfection of human embryonic kidney cells, having a low level
of endogenous p53 protein, with a dominant mutant p53 gene
resulted in increased production of vascular endothelial growth
factor (VEGF) mRNA (Kieser et al, 1994). The mechanism by
which p53 regulates angiogenesis appears to be tissue specific
because in glioblastoma an angiogenesis inhibitory activity
different from TSP-1 was controlled by the wild-type p53 gene
(Van Meir et al, 1994).
In this prospective study, to determine whether the extent of the
tumour vasculature would be a predictor of patient’s survival and
of the mode of metastasis, we compared the clinical data of 145
patients with colorectal cancer with IMD and with p53 expression
status of their primary tumour specimens.
PATIENTS AND METHODS
Patients
For this study, clinical data and tumour tissue from 170 patients
were collected between January 1991 and July 1995 at the depart-
ments of surgery of the St. Augustin General Hospital and of the
University Hospital, Antwerp, Belgium. Patients with synchro-
nous or metachronous tumours were excluded (n = 11), as were
patients who did not experience a disease-specific death (n = 8).
Six patients with incomplete follow-up data were also omitted,
resulting in 145 patients suitable for analysis.
Tumours were evaluated according to the modified
Astler–Coller clinicopathological classification. Patients did not
receive chemotherapy or radiation therapy before surgery. All had
primary tumour resection with regional lymph node dissection.
Tumour specimens were fixed in buffered formalin solution and
embedded in paraffin. Histological grading was performed on
haematoxylin and eosin (H and E)-stained sections. Standardized
adjuvant treatment was delivered to all stage C patients, with the 
5-fluorouracil and levamisole regimen (Moertel et al, 1990).
Survival was measured from the time of resection until death or
the end of July 1997, whichever came first. Haematogenous
metastasis was evaluated both at surgery and during standardized
follow-up, whereas lymphogenic metastasis was histologically
confirmed only at surgery. Prognostic information on all patients
was transferred to a dedicated computer file.
Immunohistochemical study for CD31 and p53 antigens
The staining methods have been described before (Vermeulen 
et al, 1996b). Briefly, 5-mm-thick sections, mounted on 3-amino-
propyltriethoxysilane-coated slides, were dewaxed in xylene,
rehydrated in ethanol and incubated in 0.3% hydrogen peroxide 
in methanol for 30 min. The sections were pretreated in the
microwave oven in a citrate buffer for 15 min at 95°C and left to
cool for 1 h at room temperature. Blood vessels were visualized by
staining endothelial cells for CD31 (mouse monoclonal antibody
JC70, Dako, Prosan, Belgium). On a parallel section, immuno
staining for the p53 protein was performed by applying the mouse
monoclonal antibody DO7 (Biogenex, Klinipath, Belgium), recog-
nizing both the mutant and the wild-type p53 protein. A standard
double peroxidase/antiperoxidase technique was used with
diaminobenzidine tetrahydrochloride as chromogen. A light H and
E counterstain was applied. Negative controls consisted of omis-
sion of the primary antisera.
Determination of intratumoural microvessel density
IMD was assessed according to the international consensus report
(Vermeulen et al, 1996a). One section per tumour was analysed.
The entire section was systematically scanned at ´ 100 magnifica-
tion to identify the areas of most intense neovascularization,
commonly called ‘hot spots’. Those were identified as having the
highest density of brown-staining, CD31-positive cells or cell
clusters. Vascular hotspots were suitable for analysis provided
they were adjacent to tumour cells. Whenever such a highly vascu-
larized area was encountered at ´ 100 magnification, individual
microvessels were counted in a single ´ 200 field (0.61 mm2) in
this area. Any brown-staining structure clearly separated from
adjacent microvessels was regarded as a single, countable
microvessel. Neither vessel lumens nor the presence of red blood
cells were used to define a microvessel, and no exclusion criteria
based on size were used. Occasional immunopositive
macrophages and plasma cells were excluded on morphological
grounds. After vessels in the ´ 200 field were counted, scanning of
the tumour section at ´ 100 magnification was continued until
analysis of the entire section. The mean of the five highest counts
per tumour was taken for further analyses and was expressed as
microvessels per field at magnification ´ 200. The predefined cut-
off value for categorical evaluation of IMD was the median IMD
of the population studied.
Determination of p53 expression
p53 expression was graded semiquantitatively. If more than 10%
of all tumour cell nuclei were stained, the tumour was regarded as
positive. This cut-off value was also predefined at the start of the
study.
Statistical analysis
The clinical characteristics of the patients in relation to IMD were
compared by Mann–Whitney U-test and c2 test. The survival
curves were plotted according to the Kaplan–Meier method and
differences were validated by Mantel–Cox logrank testing. The
influence of various factors on overall survival was assessed by
multiple regression by the Cox proportional hazards model. For 
all analyses, the Statview 4.0 application (Abacus Concepts,
Berkeley, CA, USA) was used. A value of P < 0.05 was considered
statistically significant.
RESULTS
Patients
Median age at diagnosis was 66 years (range 25–88). Median
follow-up time was 30 months (range 2–77). Median follow-up of
the surviving patients was 43 months (range 24–77). Half of the
patients had died after 59.7 months (s.e. 14.5). The male/female
ratio was 1.08. Five patients (4%) had stage A disease, 44 (30%)
had stage B disease (three B1, 35 B2 and six B3), 67 (46%) had
stage C disease (three C1, 54 C2, ten C3), and 29 (20%) had stage D
disease. In 112 patients (77%), the tumour was located in the left318 PB Vermeulen et al
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colon or rectum. In 33 patients (23%), the tumour was located in
the right or transverse colon. One quarter of all patients had a
rectal tumour. Median tumour size was 40 mm (range 15–120).
Astler–Coller stage was significantly associated with survival 
(P < 0.0001). None of the stage A patients died during the study.
Survival of stage B and stage C patients was comparable, with
respective 5-year survival rates of 65% [95% confidence interval
(95% CI) 45–85] and 58% (95% CI 43–73). Survival of stage C3
patients was inferior to the survival of other stage C patients (P =
0.0002). The overall survival rate of 5 years of this group was 15%
(95% CI 0–40) and the overall survival rate of 3 years was 30%
(95% CI 2–58). All patients with stage D tumours had died within
3 years after surgery.
Intratumoral microvessel density and overall survival
Median IMD of all patients was 74 (range 39–188). Median IMD
of patients undergoing curative surgery (stages A–C) was 75
(range 39–188; n = 116). IMD was not related to Astler–Coller
stage (P > 0.1). The median IMD of tumours of patients younger
than 66 years was significantly higher than the median IMD of
tumours of older patients: 83 compared with 66 respectively 
(P = 0.035). Linear regression analysis of IMD vs age resulted 
in a coefficient r of –0.2 (P = 0.037).
When regarded as a continuous variable, a trend of increasing
IMD being related to shorter survival in patients undergoing
surgery with curative intent was observed [hazard ratio expressed
per increment of one microvessel = 1.01 (95% CI 1.00–1.02), 
P = 0.08]. In Astler–Coller stage D patients, there was no relation
between IMD and survival.
The 116 patients with stages A–C tumours were
dichotomized by the median IMD of 75 into two subgroups: 57
patients with hypovascular tumours and 59 patients with hyper-
vascular tumours. The c2 analysis demonstrated that tumour
site, tumour size, differentiation grade, depth of penetration,
p53 protein expression status and the presence or absence of
lymph node metastasis were equally distributed among the two
subgroups (Table 1). Younger patients and tumours with more
than three metastastic lymph nodes were more frequent in the
hypervascular subgroup, although this was only a statistical
trend.
Haematogenous metastasis was significantly more frequent in
the hypervascular subgroup (P = 0.001) (Table 1). The survival
rates of the two subgroups calculated using the Kaplan–Meier
method were significantly different in favour of the hypovascular
group (P = 0.005; Figure 1). Although 72% (95% CI 52–92) of the
hypovascular group reached the overall survival rate of 5 years,
only 51% (95% CI 37–66) of the hypervascular group survived for
Table 1 Comparison of clinicopathological features between patients undergoing curative
surgery with hypovascular and those with hypervascular tumours
Variable Hypovascular Hypervascular P-value
IMD < 75 IMD ³ 75
(n = 57) (n = 59)
Agea
< 66 24 (41) 35 (59) 0.06
³ 66 33 (58) 24 (42)
Tumour site
Left, rectum 45 (48) 48 (52) NS
Right transverse 12 (52) 11 (48)
Tumour sizeb
< 4 cm 28 (42) 38 (58) NS
³ 4 cm 29 (58) 21 (42)
Tumour histology
Well–mod. differentiated 50 (49) 53 (51) NS
Poorly differentiated 7 (54) 6 (46)
Depth of penetrationc
T1, T2 6 (60) 4 (40) NS
T3, T4 51 (48) 55 (52)
p53 expression
– 20 (42) 27 (58) NS
+ 37 (54) 32 (46)
Lymph node metastasisd
Negative 27 (56) 21 (44) NS
Positive 30 (45) 37 (55)
≤ 3 50 (54) 43 (46) 0.06
> 3 7 (32) 15 (68)
Haematogenous metastasis
Negative 48 (59) 34 (41) 0.001
Positive 9 (26) 25 (74)
a,bCut-off value is the median value; cT1, penetrates to submucosa; T2, penetrates to subserosa;
T3, serosa (exposed); T4, infiltrating the neighbouring tissue; devaluated at surgery.Angiogenesis, p53 and survival in colorectal cancer 319
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that period. An IMD of 75 or more yielded a relative risk of cancer
death of 2.85 (95% CI 1.33–6.09). A high IMD was associated
with inferior survival also when tertiles were used as cutoff values.
The respective overall survival rates of 5 years for high, interme-
diate and low IMD groups were 51% (95% CI 33–70), 56% (95%
CI 34–77) and 76% (95% CI 54–99) (P = 0.040). In the 29 patients
with stage D tumours, no association of IMD with survival was
found.
Of the 116 patients with stages A–C tumours, 20 patients (17%)
had a hypovascular tumour without p53 overexpression. The
overall survival rate of 5 years was 100% in this group compared
with 58% (95% CI 42–75) in the group of tumours being hyper-
vascular or overexpressing p53, and 51% (95% CI 32–71) in the
group of tumours being hypervascular and overexpressing p53 
(P < 0.01). There was no difference in the distribution of A–C
stages in the three groups (P > 0.1). The same survival analysis
was performed for stage B and stage C tumour patients separately
(Figure 2A and B). Of all stage B tumour patients, 23% had an
unfavourable prognosis and 20% had an extremely favourable
prognosis. A decision to treat or not might, thus, be facilitated in
43% of all stage B tumour patients. Of all stage C patients, 15%
might not need adjuvant treatment on the basis of IMD and p53
expression. There was no difference in the distribution of
substages according to depth of invasion in the different p53–IMD
groups (P > 0.1).
The prognostic value of IMD in patients undergoing curative
surgery was examined by multivariate analysis using the Cox
proportional hazards model (Table 2). IMD was identified as a
significant and independent prognostic factor. Tumour size
attained borderline significant prognostic value. A statistical trend
towards prognostic significance was reached for differentiation
grade, p53 protein expression status and age. When, in a second
model, lymph node metastasis was expressed as more or less than
three nodes involved, this was also not associated with survival.
Size now became a significant prognostic factor. All other P-
values did not change.
Intratumoral microvessel density and mode of metastasis
Of the 116 stages A–C tumour patients, 34 (29%) developed
haematogenous metastasis after surgery. Median IMD in this
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Figure 2 (A) Overall survival curve for patients with stage B tumours
according to intratumoral microvessel density (IMD) and p53 overexpression.
Patients with tumours characterized by IMD < 75 (IMD low) and no p53
expression (p53 neg) had better survival than patients with IMD ³ 75 (IMD
high) and p53 expression (p53 pos) [P < 0.03 by logrank (Mantel–Cox) test].
(B) The same survival analysis as for stage B tumours was performed for
stage C tumours
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Figure 1 Overall survival curve for patients with stages A–C tumours.
Survival of 57 patients with hypovascular tumours [intratumoral microvessel
density (IMD) < 75, solid line) was significantly greater than that of the 59
patients with hypervascular tumours (IMD ³ 75, dashed line). P = 0.0047 by
logrank (Mantel–Cox) test
Table 2 Association of various factors with overall survival determined by the Cox proportional
hazards model for patients undergoing curative surgery
Prognostic factors Hazards ratio 95% Confidence limits P-value
Age (< 66 vs. ³ 66)a 1.93 0.89–4.20 0.098
Tumour site (left, rectum vs. right,
transverse) 1.58 0.48–5.16 0.453
Tumour size (> 40 vs. ≤ 40 mm)a 2.16 0.99–4.74 0.054
Histology (poorly differentiated vs. other) 3.45 0.90–13.25 0.072
Tumour depth (T3,4 vs. T1,2) 1.97 0.26–14.92 0.512
Lymph node metastasis (+ vs. –) 1.13 0.50–2.53 0.774
p53 (+ vs. –) 2.21 0.91–5.37 0.079
IMD (³ 75 vs. < 75)a 3.26 1.41–7.55 0.006
aCut-off value is the median value.320 PB Vermeulen et al
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group was higher than in the group of patients without haematoge-
nous metastasis: 87 compared with 72 (P = 0.004). There was no
difference in IMD between patients with and without lymph node
metastasis detected at surgery. The prevalence of haematogenous
metastasis, but not of lymph node metastasis, increased as IMD
increased per tertile (P = 0.011) (Figure 3). Median IMD of stage
D tumours was 69, and was significantly lower than the median
IMD of stages A–C tumours of patients who developed
haematogenous metastasis after surgery (P = 0.023).
DISCUSSION
This prospective study confirms the prognostic value of IMD in
colorectal cancer patients previously suggested by retrospective
studies, and demonstrates the additive prognostic value of IMD
and p53. Analysis of the relation of IMD with mode of metastasis
reveals a positive association of IMD with the incidence of
haematogenous metastasis in colorectal cancer patients. All signif-
icant results are restricted to patients treated by surgery with cura-
tive intent, thus excluding Astler–Coller stage D tumour patients.
In eight retrospective studies, a significant correlation between
high IMD and shorter survival in colorectal cancer was found by
univariate analysis (Saclarides et al, 1994; Frank et al, 1995;
Tomisaki et al, 1996; Engel et al, 1996; Takebayashi et al, 1996a,
1996b; Takahashi et al, 1997; Tanigawa et al, 1997). In five of
these studies, a multivariate analysis was performed, by which in
four out of the five studies the prognostic value of IMD was
confirmed. In three reports, IMD in the primary tumour was posi-
tively correlated with respectively platelet-derived endothelial cell
growth factor (PdECGF) expression (Takebayashi et al, 1996b),
VEGF expression and p53 protein overexpression (Kang et al,
1997), and IMD in the liver metastases in stage D tumour patients
(Mooteri et al, 1996). In univariate analysis, high PdECGF expres-
sion (Takebayashi et al, 1996b) and low IMD in the liver metas-
tases (Mooteri et al, 1996) were associated with inferior survival.
One study reported a lack of correlation between IMD and survival
in colorectal cancer (Bossi et al, 1995) and another study yielded a
significant association between high IMD and longer survival,
both in uni- and multivariate analysis (Lindmark et al, 1996).
Interestingly, the last two studies are based on a methodology
which deviates considerably from the microvessel counting
method originally introduced by Weidner et al (1991) and recently
modified in an international consensus report (Vermeulen et al,
1996a).
Wild-type p53 expression has been shown in vitro to restrict the
ability of cells to induce angiogenesis (for review: Bouck, 1996).
In colorectal cancer, IMD has been reported to be higher in
tumours characterized by the accumulation of an afunctional p53
protein, as detected by immunohistochemistry (Vermeulen et al,
1996b; Kang et al, 1997). Although we have not been able to
confirm this, patients with tumours without p53 protein accumula-
tion combined with a low IMD had a significantly better survival
than other patients. This additive prognostic power of IMD and
p53 status has been reported in node-negative breast carcinoma
(Gasparini et al, 1994). It might be that mutant p53 is responsible
for the secretion of factors which induce remodelling of the
tumour vasculature. This might lead, in highly vascularized
tumours, to more extensive mitogenic paracrine signalling towards
malignant cells than in less vascularized tumours (Folkman,
1996). In contrast, high IMD might be the reflection of other genes
besides p53 residing in a state in which they both augment angio-
genesis and accelerate tumour growth, like the mutated ras gene
(Rak et al, 1995).
The incidence of distant relapse was higher in well-vascularized
tumours. This observation supports the theoretical basis of
counting microvessels in areas which are most densely vascular-
ized. Tumour cells are expected to intravasate more easily when
surrounded by a larger surface area of endothelial cells or by more
newly formed vascular sprouts. Proliferating and migrating
endothelial cells digest the extracellular matrix by different
proteases (Brooks et al, 1996), and stimulate tumour cell activity
by paracine pathways (Folkman, 1996). We have observed a two-
fold higher endothelial cell proliferation rate in vascular hotspots
compared with unselected regions in colorectal cancer specimens
(Vermeulen et al, 1995b). In breast cancer, tumour cell shedding
during surgery was positively correlated with the number of
microvessels per surface area in the vascular hotspots (McCulloch
et al, 1995). In bone marrow aspirates from breast cancer patients
before surgery, the likelihood of detecting micrometastases was
positively associated with tumour vascularity and with vascular
invasion (Fox et al, 1997).
Although the prevalence of lymph node metastasis at surgery
was not associated with IMD in the primary tumour, patients with
more than three involved lymph nodes more frequently had hyper-
vascular tumours. Halting angiogenesis by antibodies blocking the
VEGF receptors has recently been shown to suppress tumour cell
invasion as well (Skobe et al, 1997). This is in direct support of the
concept that endothelial or other stromal cells are responsible for
at least part of the malignant phenotype of tumour cells, and might
explain the observed relation between lymphogenic metastasis and
IMD. In addition, tumour cell clones trapped in lymph nodes
might grow more easily to a detectable size if they elicit more
microvessels. The angiogenic phenotype of the metastatic cells
probably reflects the angiogenic capacity of the primary tumour.
An explanation for the lack of association between IMD and
survival in stage D tumour patients is not obvious. Survival of
patients after resection of these tumours might at least be partly
influenced by IMD in the metastasis. Low IMD in liver metastasis
of 32 stage D patients has been found to predict shorter survival
(Mooteri et al, 1996). IMD of the metastases reflected IMD of the
primary colorectal tumours. A hypothetical explanation for the
lack of association between IMD and survival is based on the
highly invasive nature of stage D tumours. It is conceivable that
tumour cells with these properties can migrate and proliferate in
the stromal tissue of highly vascularized target organs without the
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Figure 3 Metastatic disease among 116 patients with stages A–C in
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need to elicit microvessel development. Such an angiogenesis-
independent growth pattern has been observed in tumours in the
lungs and in the liver (McGuire et al, 1997; Pezzella et al, 1997).
In this way, the angiogenic properties of the primary tumour,
reflected in the IMD value, would not necessarily be related to the
potential of metastases to expand. A second explanation might be
that Astler–Coller or Dukes’ stage is not simply determined by the
duration between initiation and diagnosis of colorectal cancer. Our
observation of a significant difference between IMD of stage D
tumours and IMD of stages A–C tumours of patients who devel-
oped metastases during follow-up supports this view. Moerkerk et
al (1994) have shown that both the number and the type of Ki-ras
oncogene mutations are related to Dukes’ stage.
The observation of decreasing IMD with increasing age is
supported by several animal experiments, and is in accordance
with slower tumour growth rates and less frequent metastasis in
old animals under experimental conditions (Ershler et al, 1997).
As the selection of colorectal cancer patients likely to benefit
from adjuvant chemotherapy remains difficult, the clinical valida-
tion of the results of this prospective study seems warranted.
Based on IMD and p53 status, a selection of stage B tumour
patients prone to early relapse should be randomized between
adjuvant treatment or not. Other prognostic indicators, such as
chromosome 18q loss of heterozygosity, may be compared with
IMD and p53 expression to identify stage B tumour patients at
high risk for recurrence (Ogunbiyi et al, 1998). In the same way, a
fraction of stage C tumour patients with reduced risk for recurrent
cancer can be excluded from further treatment.
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